ABSTRACT
Anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) assays are widely performed because they are part of the laboratory criteria for the antiphospholipid syndrome (APS). Despite several standardization workshops and the availability of a worldwide accepted calibrator material for aCL, a high variability in numerical assay results and in sample classification is still observed in comparative studies and external quality control surveys. For anti-β2GPI assays, comparison of numerical values is impeded by the absence of a common calibrator material, and external quality surveys similarly show a large overlap in sample classification. Numerous variables impact assay results, among them the source and integrity of β2GPI, the secondary calibration process, and the assessment and derivation of cutoff values. For both assays, the vast majority of laboratories use commercial kits whose number has risen considerably in the past years. However, many problems persist, and there is a need to improve the comparability in assay results. The use of monoclonal antibodies as reference calibrators has to be especially considered, with their suitability evaluated by future collaborative studies and external quality controls surveys. Manufacturers should provide more precise information on results obtained when testing control groups for establishing reference ranges and cutoff values. From the customers' perspective, it is important that each laboratory, even if using commercial kits, assesses its local cutoff value whenever possible. In the field of autoimmunity, assay standardization is a difficult but nevertheless important task. Much more effort is needed to reduce the high interlaboratory variability in assay results even if absolute standardization cannot be feasibly achieved.
KEYWORDS
Anticardiolipin antibodies - anti-β2 glycoprotein I antibodies - assays - standardization
REFERENCES
-
1
Harris E N, Gharavi A E, Boey M L et al..
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systematic lupus erythematosus.
Lancet.
1983;
2
1211-1214
-
2
Loizou S, McCrea J D, Rudge A C, Reynolds R, Boyle C C, Harris E N.
Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.
Clin Exp Immunol.
1985;
62
738-745
-
3
Harris E N, Gharavi A E, Patel S P, Hughes G R.
Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.
Clin Exp Immunol.
1987;
68
215-222
-
4
Harris E N.
Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.
Am J Clin Pathol.
1990;
94
476-484
-
5
Harris E N, Pierangeli S, Birch D.
Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies.
Am J Clin Pathol.
1994;
101
616-624
-
6
Coulam C B, McIntyre J A, Wagenknecht D, Rote N.
Interlaboratory inconsistencies in detection of anticardiolipin antibodies.
Lancet.
1990;
335
865
-
7
Peaceman A M, Silver R K, MacGregor S N, Socol M L.
Interlaboratory variation in antiphospholipid antibody testing.
Am J Obstet Gynecol.
1992;
166
1780-1784
-
8
Galli M, Comfurius P, Maassen C et al..
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.
Lancet.
1990;
335
1544-1547
-
9
McNeil H P, Simpson R J, Chesterman C N, Krilis S A.
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci U S A.
1990;
87
4120-4124
-
10
Matsuura E, Igarashi Y, Fujimoto M et al..
Anticardiolipin cofactor (s) and differential diagnosis of autoimmune disease.
Lancet.
1990;
336
177-178
-
11
Viard J P, Amoura Z, Bach J F.
Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus.
Am J Med.
1992;
93
181-186
-
12
Wilson W A, Gharavi A E, Koike T et al..
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.
Arthritis Rheum.
1999;
42
1309-1311
-
13
Miyakis S, Lockshin M D, Atsumi T et al..
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost.
2006;
4
295-306
-
14
Reber G, Arvieux J, Comby E et al..
Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hémostase et la Thrombose).
Thromb Haemost.
1995;
73
444-452
-
15
Tincani A, Allegri F, Sanmarco M et al..
Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations—a cooperative project of the European Antiphospholipid Forum.
Thromb Haemost.
2001;
86
575-583
-
16
Reber G, Schousboe I, Tincani A et al..
Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group.
Thromb Haemost.
2002;
88
66-73
-
17
Audrain M A, Colonna F, Morio F, Hamidou M A, Muller J Y.
Comparison of different kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein 1.
Rheumatology.
2004;
43
181-185
-
18
Kutteh W H, Franklin R D.
Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers.
Am J Obstet Gynecol.
2004;
191
440-448
-
19
Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa M C. European Forum on Antiphospholipid Antibodies Standardization Group .
Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays.
Thromb Haemost.
2005;
94
665-672
-
20
Favaloro E J, Silvestrini R.
Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing.
Am J Clin Pathol.
2002;
118
548-557
-
21
Favaloro E J, Wong R C, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P.
A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing.
Semin Thromb Hemost.
2005;
31
73-84
-
22
Favaloro E J, Wong R C, Jovanovich S, Roberts-Thomson P.
A review of beta2-glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program.
Am J Clin Pathol.
2007;
127
441-448
-
23
Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A.
Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity.
Thromb Res.
2007;
120
127-133
-
24
Chamley L W, Pattison N S, McKay E J.
Anomalous anticardiolipin antibody results may be due to cofactor variability.
Am J Hematol.
1991;
37
289
-
25
Matsuura E, Inagaki J, Kasahara H et al..
Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship.
Int Immunol.
2000;
12
1183-1192
-
26
Pierangeli S S, Stewart M, Silva L K, Harris E N.
An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies.
J Rheumatol.
1998;
25
156-160
-
27
Ichikawa K, Khamashta M A, Koike T, Matsuura E, Hughes G R.
beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome.
Arthritis Rheum.
1994;
37
1453-1461
-
28
Matsuura E, Igarashi Y, Yasuda T et al..
Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.
J Exp Med.
1994;
179
457-462
-
29
Tsutsumi A, Ichikawa K, Matsuura E, Sawada K I, Koike T.
Heterogeneous behavior of anti-beta2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with beta2-glycoprotein I.
J Rheumatol.
2000;
27
391-396
-
30
Brighton T A, Dai Y P, Hogg P J, Chesterman C N.
Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids.
Biochem J.
1999;
340
59-67
-
31
Sanmarco M, Bardin N, Blank M et al..
Heterogeneity of anti-beta2-glycoprotein I antibodies. A factor of variability in test results.
Thromb Haemost.
2005;
93
80-87
-
32
de Laat B, Derksen R H, Urbanus R T, de Groot P G.
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.
Blood.
2005;
105
1540-1545
-
33
de Laat B, Derksen R H, van Lummel M, Pennings M T, de Groot P G.
Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change.
Blood.
2006;
107
1916-1924
-
34
Tincani A, Allegri F, Balestrieri G et al..
Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies.
Thromb Res.
2004;
114
553-558
Dr. Guido Reber
Haemostasis Unit, Geneva University Hospital, 25 rue Micheli-du-Crest
1211 Geneva 14, Switzerland
eMail: guido.reber@hcuge.ch
